Under their collaboration, BeiGene agreed to jointly develop 20 Amgen oncology pipeline assets globally—including targeted small-molecule agents such as AMG 510, a first-in-class investigational KRAS G12C inhibitor, as well as BiTE ® (Bispecific T cell Engager) antibodies, for solid and hematologic malignancies. Eight treatments by 2020 "We are thrilled to join forces with Amgen to realize the development and commercialization of this broad oncology pipeline with the aim of benefitting patients around the world," John V. Oyler, BeiGene's co-founder, CEO, and chairman, said yesterday in a statement issued after the close of financial markets. "This alliance expands the portfolio available to our market-leading China commercial team, led by Xiaobin Wu, PhD, with the potential to bring as many as eight internally discovered and in-licensed innovative treatments to cancer patients by the end of 2020."